De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma

PURPOSE: Despite the success of targeted therapy in c-ros oncogene 1 (ROS1)-rearranged cancers, especially non-small cell lung cancer (NSCLC), the clinical significance of ROS1 de novo mutation has not yet been understood. We sought to elucidate the predictive effect of ROS1 mutation for immune chec...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Front Oncol
Main Authors: Ma, Si-Cong, Zhu, Hong-Bo, Wang, Jian, Zhang, Yan-Pei, Guo, Xue-Jun, Long, Li-Li, Guo, Ze-Qin, Wu, De-Hua, Dong, Zhong-Yi, Bai, Xue
Format: Artigo
Sprog:Inglês
Udgivet: Frontiers Media S.A. 2021
Fag:
Oncology
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247586/
https://ncbi.nlm.nih.gov/pubmed/34221982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.666145
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker